Daniel L. Kisner, Director at Zynerba Pharmaceuticals, Inc. (ZYNE), sold 115 shares at $0.35 ($40) on 2023-06-14, disclosed to the SEC on 2023-06-15.
Open-market sale of $40 ZYNE by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| CNAT | BUY | 2015-04-10 | $23K | — | Filing → |
| DVAX | BUY | 2013-10-30 | $11K | — | Filing → |
| CALP | SELL | 2008-06-05 | $4K | — | Filing → |